Wegovy maker Novo Nordisk bets big on talent, AI partnerships in India
Novo to double global process leaders in India in 3-4 years
Novo has partnered with 10 Indian AI start-ups for various tasks
India centre to mirror Denmark HQ in handling R&D data, exec says
Other drugmakers ramping up operations in India as well
By Rishika Sadam and Haripriya Suresh
BENGALURU, Oct 11 (Reuters) -Novo Nordisk NOVOb.CO, whose global profile has risen along with demand for its Wegovy weight-loss drug, is bolstering operations in the world's most populous nation by beefing up senior leadership in India and partnering with local AI start-ups, a top executive told Reuters.
The moves are part of an expansion of the Danish drugmaker's operations in Bengaluru, which launched 17 years ago. The centre helps manage massive amounts of data collected on the safety and efficacy of its medicines, including information from clinical trials and reports of potential side effects.
The company, which has become among the world's most valuable due to soaring demand for Wegovy and related diabetes drug Ozempic, will double the number of global process leaders based in India over the next three to four years, and boost its overall headcount by 16% to 5,000 next year, John Dawber, Novo's managing director for global business services, said.
Novo also has partnerships with 10 start-ups in India to use artificial intelligence for a host of tasks including summarizing documents, extracting insights and checking for editing errors, Dawber said, adding that some of these AI tools are being used across its global operations.
The company's medical writers are using AI to reduce the time needed for quality checks on documents, some intended for submission to drug regulators in various required formats in countries ranging from the U.S. to Japan.
"It goes from 40 hours per document to about 40 minutes per document," Dawber said in an interview in Bengaluru.
Dawber said he expects the India centre to emerge as "an almost perfect mirror image" of the company's Bagsvaerd, Denmark headquarters in three years in terms of handling data central to research and development.
"It's still and always will be a shared activity. But certainly, the pendulum is swinging towards more responsibility for the today and the future products here in Bengaluru," he said.
BETTING ON INDIA
Novo is not the only major pharmaceutical company betting big on India.
Earlier this year, French drugmaker Sanofi SASY.PA revealed plans to invest $437 million in its India centre.
Bristol Myers Squibb BMY.N confirmed it expected its Hyderabad, India facility to become its largest unit outside the U.S. by 2025 as it looks to enhance drug development through the use of AI and digital technologies.
Half of Novo's global safety assessment work, which tracks reports of drug side effects and shares them with health regulators across the globe, is handled by its India operation.
Dawber's team in India also contributes to producing safety update reports, brochure updates through the drug development process, risk management plans and other publications.
Novo did not comment on the amount it has invested in expanding the India centre or its AI partnerships, but confirmed it was open to collaborating with more such startups in India.
Wegovy and rival drugs from Eli Lilly LLY.N sold under the brand names Mounjaro and Zepbound belong to a class of therapies known as GLP-1 receptor agonists that help control blood sugar and slow digestion, making people feel full longer.
Novo and Lilly have plans to launch their drugs in India as they compete for a global weight-loss market some analysts have said could reach $150 billion in the next decade.
Reporting by Rishika Sadam and Haripriya Suresh; Editing by Dhanya Skariachan and Bill Berkrot
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
